SecBot SecBot
SECBOTREPLAY Home › Report › ANIP

ANIP · ANI Pharmaceuticals published an updated May 2026 investor presentation…

ANI PHARMACEUTICALS INC · 8-K filed May 13, 2026 at 08:27 ET

At the news

BULLISHIMPACT 7/10

8-K filed May 13, 2026 at 08:27 ET

ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reiterating and raising its full-year 2026 guidance originally provided on May 8, 2026. The presentation highlights strong Q1 2026 results with total net revenue of $237.5M (+20% YoY) and adjusted non-GAAP EBITDA of $63.0M (+24% YoY), driven by Cortrophin Gel momentum and a new IP license fee. The company raised its 2026 revenue guidance to $1.08B-$1.14B (from $1.055B-$1.115B) and adjusted EBITDA guidance to $285M-$300M (from $275M-$290M), and authorized a new $100M share repurchase program.

  • Q1 2026 total net revenue of $237.5M, up 20% YoY from $197.1M
  • Q1 2026 adjusted non-GAAP EBITDA of $63.0M, up 24% YoY from $50.7M
  • Raised full-year 2026 total net revenue guidance to $1.08B-$1.14B (prior: $1.055B-$1.115B)
  • Raised full-year 2026 adjusted non-GAAP EBITDA guidance to $285M-$300M (prior: $275M-$290M)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access